Britain and America have hammered out a key trade agreement that will keep no tariffs on British medicine exports being sold in the US market.
The Terms of the Pact
As part of the deal, the UK has committed to increase expenditure on medicines through the NHS. This move secures that duties on these crucial exports will stay at zero for a duration of 36 months.
This development comes after recent threats to dramatically increase duties on branded pharmaceutical imports, with figures discussed up to 100%.
"This arrangement between the UK reinforces the global environment for innovative medicines and brings long-overdue fairness to U.S.–U.K. drug exports," a release noted.
Trade Importance
Pharmaceuticals are one of the the United Kingdom's most significant export categories to the America, which is clearly the primary market for leading UK drugmakers.
Statistics show that in the year to the end of September, the UK exported drugs totaling over eleven billion pounds to the US. This amount made up nearly one-fifth of total UK exports in that span.
"This deal secures employment, boosts investment and paves the way for the UK to emerge as a international leader for medical research," a minister commented.
Specific British Pledges
The deal includes several specific pledges from the UK:
- Higher Cost Ceiling: The UK will increase the price threshold at which it deems new treatments to be prohibitively costly by 25%.
- Increased NHS Spending: There is a aim to double total public funding on drugs from 0.3% of GDP to 0.6% over the coming ten years.
- Refund Ceiling: The sum pharmaceutical firms must return to the NHS to control costs will be capped at fifteen percent. Last year, repayments topped twenty percent.
Recent Tensions
The pact follows a protracted dispute between the drug companies and the British authorities over medicine costs and approval rates.
This friction were exacerbated by arguments that US customers were charged several times more for the same drugs than patients in the other developed nations.
Over the last 18 months, several major pharmaceutical investments in the UK have been paused or cancelled, while major expansions have been directed toward US facilities.
The Science Minister publicly accepted that the NHS needed to increase expenditure on medicines, noting that its budget allocation on drugs had shrunk as a share of its overall budget over the previous ten-year period.
